Health
Iris on health and longevity · June 15th
storyflo · health and longevity
Jun 15, 2026 · 2 min listen
Listen · storyflo · health and longevity
Iris on health and longevity · June 15th
0:00-1:59
Live · Kokoro-82M
The evidence behind breast‑cancer screening is solid—large randomized trials and meta‑analyses show that regular mammography reduces mortality, especially when started at the right age for a person’s risk level. For most women with average risk, starting at 40 or 45 years and screening every two years is well supported; higher‑risk groups (family history, genetic mutations) may benefit from earlier, annual imaging and often add MRI to catch cancers that mammograms miss.
Risk isn’t just age. Tools that combine family history, breast density, and lifestyle factors can stratify women into low, moderate, or high risk, guiding both the start age and the interval between screens. The higher the risk, the more frequent and comprehensive the imaging should be, but the trade‑off is more false positives and follow‑up tests, so it’s a personal balance.
Choosing the right imaging strategy depends on what the breast tissue looks like. Dense breasts can hide tumors on standard mammograms, so adding ultrasound or MRI improves detection, though MRI is more costly and requires contrast. For most women with fatty or moderately dense tissue, a standard digital mammogram is sufficient; for those with very dense tissue, supplemental ultrasound or MRI may be worth discussing.
Ultimately, the decision hinges on a shared conversation: weigh the modest benefit of earlier detection against the potential anxiety and extra procedures. If you’re unsure where you fit, a brief risk assessment with your clinician can clarify whether you should start earlier, screen more often, or stick with the standard schedule.
So I was reading through some comments from a recent post, and a lot of people were sharing their own struggles with considering leaving a marriage, even when their partner is a good person. One comment in particular stuck with me, from someone who's torn about leaving a loving relationship because they're unsure if it's the right decision. They're worried about regret and losing something valuable.
I totally get it, because I've been in that same spot before. It's a really tough and emotional place to be. The thing is, there's no one-size-fits-all answer here, but I do want to share some thoughts that might be helpful.
When you're thinking about leaving a marriage, it can be really hard to know what to do. You might feel like you need to have all the answers, but the truth is, you might not ever have complete certainty. What's important is taking the time to really think about what you want and what's best for you.
It's also important to consider what's driving your desire to leave. Is it something specific that's not working in the relationship, or is it more of a general feeling of discontent? Being honest with yourself about your reasons can help you make a more informed decision.
Ultimately, the decision to leave a marriage is a personal one, and it's not something that anyone else can make for you. But I do want to say that it's okay to take your time and to be unsure. It's okay to not have all the answers right now. What's most important is being kind to yourself and taking care of your own emotional well-being as you navigate this difficult decision.
Rocket Pharmaceuticals received the rare pediatric disease priority review voucher with the accelerated FDA approval for Kresladi in March. The non-dilutive capital from the voucher’s sale will support a pipeline that includes a gene therapy in pivotal clinical testing for the rare genetic disorder Danon disease. The post Rocket Pharma Reaps $180M From Sale of FDA Drug Review Fast Pass appeared first on MedCity News.
Paul Markovich, president and CEO of Ascendiun, shared his ideas for bringing down healthcare costs, including digital health records and changing how healthcare is paid for. The post Paul Markovich’s 4 Ideas to Reduce Healthcare Costs appeared first on MedCity News.
(MedPage Today) -- "By the actions of the ADA, we've actually got millions of people to think about it." -- Steven Kahn, MBChB, editor-in-chief of Diabetes Care, on being kicked out of the American Diabetes Association (ADA) meeting after distributing...
(MedPage Today) -- Over the next month, millions of fans will gather across North America for the FIFA World Cup. Stadiums will fill with cheering crowds. Young athletes will dream of representing their countries one day. Communities will celebrate...
(MedPage Today) -- SALT LAKE CITY -- Ben Dowse, MD, hadn't expected to treat measles when he became a doctor, but there he was, examining a newborn exposed to the virus in the womb. The infected mother had given birth just hours earlier. The...
(MedPage Today) -- CHICAGO -- Diabetes was linked with an increased risk of death among transplant recipients of four major organs, with pre-existing and new-onset diabetes both implicated, a comprehensive analysis of four types of solid-organ...
In a recent real‑world cohort of about 2.5 million adults with newly diagnosed high blood pressure, researchers looked at how often doctors actually checked for primary aldosteronism—a hormone‑driven cause of hypertension. They found that fewer than one percent of those patients were screened at all.
Among the tiny group that did get the test, roughly one in twelve turned out positive. That’s a modest but notable yield, suggesting that many cases are slipping through the cracks simply because the test isn’t ordered more routinely.
The study was observational, pulling data from electronic health records across multiple health systems, so it reflects everyday practice rather than a controlled trial. It can’t prove that broader screening would improve outcomes, but it does highlight a gap between guidelines and what’s happening on the ground.
If you’re managing hypertension and have patients with resistant or early‑onset disease, it might be worth revisiting whether a simple aldosterone‑renin test could add useful information, even if the overall numbers are still small.
(MedPage Today) -- CHICAGO -- Few men prescribed testosterone therapy received guideline-concordant diagnostic testing for androgen deficiency, and some received therapy despite contraindications, a retrospective chart review indicated. In a...
Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to storyflo · health and longevity.
We’ve simplified responses to 👍 / 👎. Past comments are archived but no longer visible.